Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Last trade$284.61
Day change-$3.87 (-1.34%)
Day range$277.49 – $308.46
Volume1,510,446
Market cap$41.83B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$41.83B
Price / earnings
—
Price / book
22.37×
Price / sales
14.38×
EV / sales
14.03×
EV / EBITDA
-221.02×
Profitability
Earnings per share
-$1.14
Return on assets
-6%
Return on equity
-8.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.04×
Current ratio
2.81×
Quick ratio
2.66×
Cash ratio
1.79×
Cash flow
Price / cash flow
196.59×
Price / free cash flow
797.28×
Free cash flow
$52.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NTRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$793.98M
$752.75M
$696.64M
$665.5M
$592.18M
$546.6M
$501.83M
$476.06M
Cost of revenue
$280.51M
$267.56M
$245.81M
$220.07M
$207.8M
$200M
$185.07M
$176.42M
Gross profit
$513.47M
$485.19M
$450.83M
$445.43M
$384.38M
$346.6M
$316.77M
$299.64M
Selling, general and administrative
$333.66M
$327.2M
$327.94M
$291.3M
$308.55M
$310.55M
$266.86M
$234.92M
Research and development
$242.43M
$228.07M
$210.7M
$175.19M
$173.41M
$146.43M
$129.08M
$129.46M
Total operating expenses
$581.8M
$560.98M
$544.35M
$468.21M
$481.96M
$456.98M
$395.94M
$364.38M
Operating income
-$68.32M
-$75.79M
-$93.52M
-$22.79M
-$97.58M
-$110.37M
-$79.18M
-$64.74M
Interest expense
-$903K
-$890K
-$892K
-$991K
-$1.05M
-$1.03M
-$1.01M
-$1.29M
Income before taxes
-$59.61M
-$67.23M
-$84.81M
-$13.33M
-$87.34M
-$100.66M
-$66.76M
-$55.13M
Income taxes
$299K
-$261K
$283K
-$60.58M
$207K
$275K
$173K
-$1.36M
Net income
-$59.91M
-$66.97M
-$85.09M
$47.26M
-$87.54M
-$100.94M
-$66.94M
-$53.77M
Net income attributable to common shareholders
-$59.91M
-$66.97M
-$85.09M
$47.1M
-$87.54M
-$100.94M
-$66.94M
-$56.09M
EBITDA
-$46.36M
-$54.6M
-$73.29M
-$10.41M
-$87.28M
-$100.51M
-$69.94M
-$56.95M
Basic earnings per share
-$0.42
-$0.47
-$0.60
$0.34
-$0.64
-$0.74
-$0.50
-$0.43
Diluted earnings per share
-$0.42
-$0.47
-$0.60
$0.34
-$0.64
-$0.74
-$0.50
-$0.43
Recent news
Company coverage with links to the original publishers.
Natera (NTRA) raised its 2026 revenue guidance to $3.005-$3.035B from $2.850-$2.910B, driven by 56% year-over-year growth in Signatera testing volume to 316,000 units. Incoming CEO Solomon Moshkevich outlined an ambitious $6B annual revenue target by 2029, supported by MRD testing expansion, international growth, and pharmaceutical partnerships. The company reported Q3 2026 revenues of $794M (34.1% growth) but posted a wider-than-expected adjusted loss of 39 cents per share. Management expanded reimbursement coverage and advanced clinical trials while maintaining a 64%-66% gross margin guidance.
Natera (NTRA) reported Q3 2026 results with adjusted EPS loss of 39 cents missing estimates, but revenues of $794 million beat expectations with 34.1% year-over-year growth. Oncology test volumes surged 60.9% and MRD testing showed strong momentum. The company raised its 2026 revenue guidance to $3.005-$3.035 billion and maintained positive cash flow expectations, though operating losses remain a concern.
Natera (NTRA) reported a quarterly loss of $0.39 per share, significantly worse than the consensus estimate of $0.17 loss, representing a -129.41% earnings surprise. While the company beat revenue expectations at $793.98 million versus estimates, it has only surpassed EPS estimates once in the last four quarters. The stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting underperformance ahead despite the stock's 70.7% year-to-date gain.
Caris Life Sciences reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03, with a 66.67% earnings surprise. Revenues reached $275.36 million, surpassing estimates by 9.75% and up from $216.83 million year-over-year. The company has beaten consensus estimates for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.